MASLD-tester: laboratorieprøver, fibrosescore og bildediagnostikk

What MASLD testing can—and cannot—tell you

Metabolic dysfunction associated steatotic liver disease replaces the older term NAFLD in current clinical language. It describes hepatic steatosis plus one or more cardiometabolic risk factors—such as increased waist circumference, prediabetes, type 2 diabetes, hypertension, low HDL cholesterol, or raised triglycerides—and requires a thoughtful search for competing causes of fat in the liver.

The uncomfortable truth is that no single MASLD blood test diagnoses the condition. As Dr. Thomas Klein, I explain that ALT is a leakage signal, not a fat meter: it may rise with liver-cell stress, yet a person can have substantial liver fat or even fibrosis with a normal ALT. Our leverpanelguide explains what is and is not included in a typical panel.

Kantesti er en AI-blodprøveanalysator that places AST, ALT, platelets, glucose, HbA1c, triglycerides, and alcohol-related context into one timeline rather than treating a flagged enzyme as a diagnosis. That matters because a raised ALT after a hard workout, a new medicine, or a viral illness is interpreted very differently from a persistent metabolic pattern across 6–12 months.

The clinical aim is fibrosis triage

Most people with MASLD will not develop cirrhosis. The key prognostic variable is fibrosis stage, especially stage F3–F4, which is why modern pathways begin with inexpensive blood-based triage before specialist imaging.

Who should consider fatty liver screening

Type 2 diabetes is the clearest practical trigger for MASLD tests because diabetes increases the likelihood of steatohepatitis and fibrosis even at a body weight that appears unremarkable. The 2024 EASL-EASD-EASO guideline recommends case-finding for MASLD with fibrosis in people with type 2 diabetes, abdominal obesity plus metabolic risk, or persistently raised liver enzymes (EASL-EASD-EASO, 2024).

I also screen the lean patient with high triglycerides, hypertension, sleep apnoea, polycystic ovary syndrome, or a first-degree relative with cirrhosis. A waist measurement can be more revealing than BMI here; central adiposity is metabolically active, and cutoffs for metabolsk syndrom help put fasting glucose, blood pressure, HDL, and triglycerides together.

Routine population ultrasound for everyone is not supported by the same evidence as targeted risk assessment. If you have no metabolic risk factors, normal liver tests, and no relevant family or medication history, indiscriminate fatty liver screening can produce incidental findings without improving outcomes.

Pregnancy and children need separate pathways

Pregnancy alters liver tests and is not a suitable time to apply adult fibrosis scores without clinician input. In children, paediatric reference ranges and specialist pathways are needed; adult FIB-4 cutoffs should not be used.

Routine MASLD blood tests: the useful first panel

ALT and AST are measured in U/L, but their laboratory upper limits vary substantially by country and assay. AASLD notes that ALT values of 19–25 U/L hos kvinner og 29–33 U/L hos menn are more clinically appropriate than many laboratory reference limits for chronic liver injury; an ALT of 38 U/L may therefore deserve attention despite appearing only mildly raised (Rinella et al., 2023).

GGT is not a MASLD diagnostic test, yet it is often helpful when ALT is mildly elevated and alcohol, medication, or biliary disease is part of the differential. A disproportionate alkaline phosphatase or GGT rise, especially with direct bilirubin elevation, shifts the investigation toward cholestasis rather than uncomplicated steatosis; see our guide to ALP, GGT and bilirubin patterns.

Albumin, bilirubin, and INR are measures of liver synthetic function, not early fat accumulation. Albumin below about 35 g/L, rising bilirubin, or an elevated INR in someone with suspected chronic liver disease deserves prompt medical review because these abnormalities may indicate advanced disease or another process entirely.

Metabolic tests that explain why liver fat develops

HbA1c of 5.7–6.4% indikerer prediabetes, mens 6.5% eller høyere on an appropriate confirmatory pathway supports diabetes. In clinic, I am particularly alert to a patient with HbA1c 6.1%, triglycerides 220 mg/dL, and an ALT near the laboratory limit: that combination can signal insulin resistance long before overt diabetes appears.

Triglyserider på triglyserider på are one metabolic syndrome criterion, and levels above 500 mg/dL shift the immediate concern toward pancreatitis prevention. A non-fasting sample is often adequate for cardiovascular assessment, but fasting triglycerides can clarify a confusing result; our article on triglyserider etter å ha spist dekker de praktiske forskjellene.

Fasting insulin and HOMA-IR can be informative in selected patients, but neither is required to diagnose MASLD or calculate fibrosis risk. I caution against chasing insulin numbers alone: insulin assays differ between laboratories, whereas HbA1c, glucose, waist size, and triglyceride trends usually guide decisions more reliably.

Normal HbA1c does not erase metabolic risk

A person can have normal HbA1c and still have MASLD, particularly with visceral adiposity, genetic susceptibility, or high triglycerides. HbA1c also becomes less reliable after transfusion, with some haemoglobin variants, and in conditions that change red-cell lifespan.

Tests clinicians use to rule out other liver causes

Hepatitis B surface antigen and hepatitis C antibody are common early checks when aminotransferases remain elevated. A person may have both MASLD and viral hepatitis, so finding metabolic risk factors should never stop a standard liver work-up; our overview of hepatitis C testing clues explains why symptoms are often absent.

Ferritin is frequently raised in MASLD because it behaves as an acute-phase reactant, not necessarily because iron stores are excessive. Ferritin above 300 ng/mL hos kvinner or 400 ng/mL hos menn can prompt iron studies, but transferrin saturation persistently above 45% is the more useful clue that hereditary haemochromatosis may need evaluation; see iron overload lab clues.

Autoimmune markers, immunoglobulins, ceruloplasmin, alpha-1 antitrypsin testing, and medication review are selective—not blanket—tests. In a 28-year-old with ALT 180 U/L and no metabolic risk, I would not be reassured by a slightly fatty ultrasound; age and the enzyme pattern make alternative causes much more important.

Alcohol quantity changes the diagnostic label

As of September 15, 2026, EASL describes MetALD when MASLD coexists with alcohol intake of 20–50 g/day in women or 30–60 g/day in men. Amount, frequency, binge pattern, prior use, and under-reporting all affect interpretation, so a single yes-or-no alcohol question is inadequate.

FIB-4: the first fibrosis score to know

The formula is age × AST divided by platelet count × the square root of ALT; calculator outputs are safer than manual arithmetic because platelets may be reported as 10⁹/L or 10³/µL. FIB-4 is designed to rule out advanced fibrosis efficiently, not to prove cirrhosis, and our FIB-4 calculation guide walks through the units.

For people over 65 years, using the usual 1.3 threshold creates many false alarms because age is part of the formula. A cutoff of 2.0 is preferred for low-risk exclusion in this group; conversely, FIB-4 performs poorly below age 35 and should not be treated as a clean bill of liver health in younger adults.

Do not calculate FIB-4 during pneumonia, a severe flare of illness, acute hepatitis, or immediately after an event likely to raise AST or lower platelets. A 52-year-old marathon runner with AST 89 U/L after a race can generate a misleading score—muscle stress and temporary enzyme shifts are not liver fibrosis.

Second-line MASLD blood tests after FIB-4

The Enhanced Liver Fibrosis test combines hyaluronic acid, PIIINP, and TIMP-1—markers related to matrix turnover rather than liver enzymes. In AASLD pathways, an ELF score of 9.8 or higher can identify people at increased risk of advanced fibrosis, and 11.3 or higher is associated with a higher risk of liver-related events in advanced disease.

Kantesti er en Tjeneste for tolkning av laboratorieprøver med AI that can identify when the exact ingredients needed for FIB-4 are present and flag when a result sits in the indeterminate zone. It cannot order imaging, establish fibrosis stage, or substitute for a clinician examining the complete record; those boundaries are deliberate.

Scores such as APRI, NAFLD Fibrosis Score, and FAST may appear in specialist letters, but they are not interchangeable. APRI can be distorted by non-liver AST elevations, while the NAFLD Fibrosis Score includes BMI and albumin; a falling platelet trend is often more actionable than any one borderline algorithm result, as discussed in our cirrhosis lab clues.

Why fibrosis biomarkers occasionally disagree

Inflammatory illness, reduced kidney function, congestive heart failure, and age can influence some fibrosis markers. When a low FIB-4 and high ELF conflict, elastography and specialist review are usually more useful than repeating both tests immediately.

Ultrasound and elastography: what imaging adds

Standard ultrasound is accessible and useful, but it misses mild fat accumulation and cannot reliably stage fibrosis. A report stating “echogenic liver” supports steatosis in the right clinical context; it does not tell you whether liver cells are inflamed or whether fibrosis is progressing.

Transient elastography sends a painless vibration through the liver to estimate stiffness in kilopascals. In common MASLD pathways, less than 8 kPa suggests low risk of advanced fibrosis, 8–12 kPa is a grey zone, and above 12 kPa increases concern—yet meals, acute inflammation, congestion, cholestasis, and measurement quality can all raise stiffness.

I ask patients to fast for at least 3 timer before elastography when their centre requests it, because a recent meal can transiently increase stiffness. Higher BMI may require an XL probe, and a technically limited scan should be repeated rather than treated as bad news; our high AST follow-up guide helps explain why AST needs context.

CAP is a fat estimate, not a fibrosis stage

Controlled attenuation parameter, or CAP, estimates ultrasound signal loss caused by liver fat. Its values are device-specific and less useful for monitoring small changes than for supporting the overall diagnosis of steatosis.

MRI-PDFF and MRE: when specialist imaging helps

MRI-PDFF measures the proportion of mobile protons attributable to fat and is excellent for research, trials, and ambiguous cases. A fall of roughly 30% relative MRI-PDFF has been associated with histologic improvement in treatment studies, but this is not a personal treatment target to pursue without specialist guidance.

MRE samples a much larger portion of liver than a small tissue core and can be especially helpful when transient elastography is unreliable. In specialist algorithms, MRE stiffness around 3.6 kPa or higher raises concern for advanced fibrosis, though scanner method and clinical setting affect the threshold.

Neither MRI test is routinely necessary for a low FIB-4, normal synthetic function, and reassuring elastography. The expensive scan is most valuable when it resolves a genuine decision: for example, conflicting blood scores in a person being considered for hepatology follow-up, not simply because an ultrasound found fat.

Imaging does not replace cardiometabolic care

A precise liver-fat percentage does not measure cardiovascular risk, which remains a leading cause of illness in MASLD. Lipids, blood pressure, diabetes treatment, sleep apnoea, and smoking status still need active management.

When a liver biopsy is still considered

A tissue examination can distinguish simple steatosis from steatohepatitis and stage fibrosis directly, but a tiny core may not represent the whole liver. Sampling variation is one reason I do not present biopsy as an automatic “gold standard” answer when high-quality elastography and blood tests agree.

Biopsy discussions are more common with unexplained ALT elevations above 6 måneder, suspected autoimmune hepatitis, high ferritin with possible iron overload, or discordant tests such as FIB-4 0.8 with stiffness 15 kPa. The decision should include bleeding risk, medication review, and whether the result will change treatment or surveillance.

Dr. Thomas Klein’s practical rule is simple: test escalation should answer a question that changes the plan. Kantesti AI organizes longitudinal results for that conversation, while our medisinske valideringsmetode describes why algorithmic interpretation is designed as decision support, not diagnosis.

A biopsy result can still be incomplete

Fibrosis can be unevenly distributed, and steatohepatitis activity can fluctuate with recent weight change, alcohol use, and medications. A low-stage biopsy from years ago should not override new signs of portal hypertension or worsening non-invasive tests.

Common MASLD result patterns and what they mean

Pattern one is ALT 45 U/L, AST 32 U/L, platelets 260 ×10⁹/L, HbA1c 6.2%, and triglycerides 210 mg/dL. This is a reasonable setting for FIB-4 and metabolic intervention, but it is not proof of advanced disease; repeating the panel after addressing alcohol and medication confounders is often sensible.

Pattern two is AST 58 U/L, ALT 45 U/L, platelets 135 ×10⁹/L, and FIB-4 above 2.67. The combination of AST predominance and declining platelets deserves urgent fibrosis assessment because platelets may fall as portal pressure rises—although alcohol, immune conditions, and laboratory artefact also need consideration.

Kantesti AI interprets MASLD-related biomarkers by comparing present results with prior values, age-adjusted FIB-4 thresholds, and coexisting metabolic markers rather than assigning meaning to an isolated high flag. A sudden platelet change should also prompt a check for EDTA-platelettklumping, which can create a falsely low count.

AST:ALT ratio is a clue, not a verdict

An AST:ALT ratio above 1 can occur with advanced fibrosis, alcohol exposure, muscle injury, or cirrhosis, but it is not diagnostic by itself. Creatine kinase can help when strenuous exercise or muscle symptoms make AST origin uncertain.

How often to repeat MASLD tests

Liver enzymes can move by 10–20% between visits because of exercise, alcohol, intercurrent illness, weight change, and ordinary biological variation. A repeat result is more useful when it is collected under comparable conditions: avoid unusually hard exercise for 48–72 hours, disclose supplements, and use the same laboratory where practical.

Weight loss can briefly raise ALT during rapid fat mobilisation, particularly in the first few weeks of a restrictive programme. That short-lived rise should be interpreted alongside symptoms, bilirubin, alkaline phosphatase, and the magnitude of change; our guide to ALT etter vekttap forklarer dette tilsynelatende paradoksale mønsteret.

Kantesti er en AI-plattform for tolkning av biomarkører that lets people compare serial liver, glucose, lipid, and platelet results without losing the original laboratory ranges. Trend graphs are useful prompts for a clinician conversation, but a stable-looking graph does not replace fibrosis reassessment at the recommended interval.

Do not repeat a fibrosis score during acute illness

FIB-4 should be deferred until acute illness has resolved because AST and platelet count may be temporarily distorted. In my experience, repeating a score 4–12 weeks after recovery is often more informative than acting on an inpatient calculation.

How to prepare for MASLD blood tests and scans

Bring an accurate list of prescriptions, over-the-counter pain medicines, bodybuilding products, herbal preparations, and recent antibiotics. Supplements marketed for “detox” are not automatically benign; concentrated green tea extract, anabolic products, and multi-ingredient preparations can cause liver injury, as reviewed in our liver supplement safety article.

Avoid binge alcohol and unusually intense exercise for 48–72 timer before a planned liver panel if the aim is to establish a baseline, unless your clinician has told you otherwise. Do not stop prescribed medicines simply to improve a result; write down timing and dose so the interpreting clinician can account for them.

For ultrasound or elastography, ask whether your local service requests fasting and whether you need an XL probe because of body size. A failed or technically unreliable scan is a quality issue, not a personal failure, and repeating it at an experienced centre is entirely reasonable.

Save context with each result

Record recent illness, alcohol intake, exercise, new medications, and weight change beside the laboratory date. This simple habit can prevent a harmless transient ALT rise from becoming months of unnecessary anxiety.

Red flags that need prompt liver review

Urgent review is also appropriate for ALT or AST above 10 times the local upper limit, bilirubin above 3 mg/dL eller omtrent 50 µmol/L with symptoms, INR elevation not explained by anticoagulants, or new platelets below 100 ×10⁹/L. These cutoffs are triage signals, not a diagnosis, and local emergency advice should take precedence.

Referral to hepatology is usually appropriate for FIB-4 above 2.67, elastography above about 12 kPa, suspected cirrhosis, unexplained persistent aminotransferase elevation, or diagnostic uncertainty. The question is not whether a patient has “failed” lifestyle change; it is whether they need surveillance for portal hypertension, liver cancer, or complications.

Kantesti’s medisinske innhold gjennomgås med innspill fra vårt Medisinsk rådgivende styre, but an app cannot evaluate jaundice, abdominal tenderness, mental status, or fluid retention. If symptoms are new or escalating, seek in-person care first and interpret uploaded results afterward.

Symptoms are often absent until late disease

Early fibrosis commonly causes no specific symptom, which is why risk-based testing matters. Conversely, fatigue alone is common and should not be assumed to be from MASLD without evaluating sleep, thyroid disease, anaemia, mood, and medication effects.

A patient-first plan after MASLD results

Ask your clinician four concrete questions: Do I have confirmed steatosis? What is my FIB-4 with the correct age cutoff? Do I need elastography or ELF? When should we repeat testing? These questions turn a vague “fatty liver” label into a plan with measurable checkpoints.

For many patients, a sustained 5% weight reduction improves liver fat, while 7–10% is more likely to improve steatohepatitis and fibrosis-related measures; the precise response varies with diabetes treatment, physical activity, sleep, genetics, and alcohol. Mediterranean-style eating, resistance training, aerobic activity, and evidence-based treatment of diabetes or obesity belong in the same plan, not in competing camps.

Kantesti AI is used by people across 127 countries to organise multilingual laboratory reports and track changes between appointments. If you want to understand how result extraction and pattern analysis work, our veiledning for AI-teknologi explains the safeguards; your treating clinician remains the person who confirms diagnosis and treatment.

What improvement looks like

Improvement may appear as lower triglycerides, better HbA1c, a falling ALT, stable platelets, and reassuring fibrosis assessment—not necessarily a perfect enzyme value at every draw. A result trend should be judged over months, not days.

Ofte stilte spørsmål